Jeffrey S. Parkin

Array ( [id] => 15436079 [patent_doc_number] => 20200032223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => METHOD FOR PRODUCING RECOMBINANT VIRUS [patent_app_type] => utility [patent_app_number] => 16/604194 [patent_app_country] => US [patent_app_date] => 2018-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11414 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -72 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15895361 [patent_doc_number] => 20200147199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => COMPOSITIONS AND METHODS RELATED TO HUMAN NEUTRALIZING ANTIBODIES TO ZIKA AND DENGUE 1 VIRUS [patent_app_type] => utility [patent_app_number] => 16/603341 [patent_app_country] => US [patent_app_date] => 2018-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36012 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16603341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20254857 [patent_doc_number] => 12427190 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => VLP-based monovalent ebola vaccines and methods of making and using same [patent_app_type] => utility [patent_app_number] => 16/494843 [patent_app_country] => US [patent_app_date] => 2018-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 1248 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16494843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15965369 [patent_doc_number] => 20200166436 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => SUBSTANCE THAT PREVENTS ANTIGEN-ANTIBODY REACTION INHIBITION BY BODY FLUID [patent_app_type] => utility [patent_app_number] => 16/498579 [patent_app_country] => US [patent_app_date] => 2018-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15046 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 154 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15797281 [patent_doc_number] => 20200121783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => GLYCAN-MASKED ENGINEERED OUTER DOMAINS OF HIV-1 GP120 AND THEIR USE [patent_app_type] => utility [patent_app_number] => 16/496912 [patent_app_country] => US [patent_app_date] => 2018-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28015 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16496912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14820957 [patent_doc_number] => 10407470 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-10 [patent_title] => Method of inducing an immune response against human immunodeficiency virus comprising administering immunogenic compositions comprising authentic trimeric HIV-1 envelope glycoproteins containing a long linker and tag [patent_app_type] => utility [patent_app_number] => 15/908372 [patent_app_country] => US [patent_app_date] => 2018-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 54 [patent_no_of_words] => 35714 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15908372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13661273 [patent_doc_number] => 10160788 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-25 [patent_title] => Stabilized human immunodeficiency virus (HIV) envelope (ENV) trimer vaccines and methods of using same [patent_app_type] => utility [patent_app_number] => 15/897554 [patent_app_country] => US [patent_app_date] => 2018-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 17412 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15897554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16185456 [patent_doc_number] => 10718771 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-21 [patent_title] => Recombinant baculoviruses and their uses in detecting arthropod-borne virus [patent_app_type] => utility [patent_app_number] => 15/892416 [patent_app_country] => US [patent_app_date] => 2018-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5498 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15892416 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13618859 [patent_doc_number] => 20180360981 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => NOVEL IMMUNOGLOBULIN VARIANTS [patent_app_type] => utility [patent_app_number] => 15/883006 [patent_app_country] => US [patent_app_date] => 2018-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 128062 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15883006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12794890 [patent_doc_number] => 20180156799 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => REAGENTS FOR HCV ANTIGEN-ANTIBODY COMBINATION ASSAYS [patent_app_type] => utility [patent_app_number] => 15/879547 [patent_app_country] => US [patent_app_date] => 2018-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7711 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15879547 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16504765 [patent_doc_number] => 20200384021 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => HIV IMMUNOTHERAPY WITH NO PRE-IMMUNIZATION STEP [patent_app_type] => utility [patent_app_number] => 16/476529 [patent_app_country] => US [patent_app_date] => 2018-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37531 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16476529 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16383405 [patent_doc_number] => 10808228 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-20 [patent_title] => Methods for increasing the infectivity of viruses utilizing alkyne-modified fatty acids [patent_app_type] => utility [patent_app_number] => 15/865713 [patent_app_country] => US [patent_app_date] => 2018-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13479 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15865713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12880798 [patent_doc_number] => 20180185441 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => Treatment of Inflammation, Autoimmune, and Neurodegenerative Disorders with Immunosuppressive Tat Derivative Polypeptides [patent_app_type] => utility [patent_app_number] => 15/850253 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19795 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 237 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15850253 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13371931 [patent_doc_number] => 20180237506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => HIGHLY ACTIVE AGONISTIC CD4 BINDING SITE ANTI-HIV ANTIBODIES (HAADS) COMPRISING MODIFIED CDRH2 REGIONS THAT IMPROVE CONTACT WITH GP120 [patent_app_type] => utility [patent_app_number] => 15/851432 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15851432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12880888 [patent_doc_number] => 20180185471 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => POLYVALENT VACCINE [patent_app_type] => utility [patent_app_number] => 15/843233 [patent_app_country] => US [patent_app_date] => 2017-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12149 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15843233 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067271 [patent_doc_number] => 20210269486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => CHIMPANZEE ADENOVIRUS CONSTRUCTS WITH LYSSAVIRUS ANTIGENS [patent_app_type] => utility [patent_app_number] => 16/467569 [patent_app_country] => US [patent_app_date] => 2017-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16467569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067271 [patent_doc_number] => 20210269486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => CHIMPANZEE ADENOVIRUS CONSTRUCTS WITH LYSSAVIRUS ANTIGENS [patent_app_type] => utility [patent_app_number] => 16/467569 [patent_app_country] => US [patent_app_date] => 2017-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16467569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17162994 [patent_doc_number] => 11149081 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-19 [patent_title] => HIV-1 GP120 CD4 binding site antibodies targeting HIV escape mutants [patent_app_type] => utility [patent_app_number] => 15/835319 [patent_app_country] => US [patent_app_date] => 2017-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 48 [patent_no_of_words] => 10771 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 234 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15835319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15324151 [patent_doc_number] => 20200002405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-02 [patent_title] => ARENAVIRUS MONOCLONAL ANTIBODIES AND USES [patent_app_type] => utility [patent_app_number] => 16/466544 [patent_app_country] => US [patent_app_date] => 2017-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17431 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16466544 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15178205 [patent_doc_number] => 20190359694 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => SEROLOGICAL ASSAY FOR ZIKA VIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 16/466161 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12964 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16466161 [rel_patent_id] =>[rel_patent_doc_number] =>)